Sanofi (NASDAQ:SNY) Earns “Hold (C)” Rating from Weiss Ratings

Sanofi (NASDAQ:SNY)‘s stock had its “hold (c)” rating reissued by equities research analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Several other analysts have also recently issued reports on SNY. Deutsche Bank Aktiengesellschaft raised Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 2nd. Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Morgan Stanley raised Sanofi from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $56.00 to $58.00 in a report on Monday, September 8th. JPMorgan Chase & Co. raised Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Finally, Barclays reaffirmed an “overweight” rating on shares of Sanofi in a report on Wednesday, July 2nd. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $62.67.

Sanofi Stock Down 0.8%

NASDAQ SNY opened at $48.80 on Wednesday. The stock’s 50 day moving average is $48.18 and its 200 day moving average is $49.92. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19. Sanofi has a 12 month low of $44.62 and a 12 month high of $60.12. The stock has a market cap of $119.83 billion, a PE ratio of 11.73, a P/E/G ratio of 1.20 and a beta of 0.51.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The business had revenue of $11.34 billion during the quarter, compared to analysts’ expectations of $9.91 billion. During the same period in the prior year, the firm posted $1.73 earnings per share. The firm’s revenue for the quarter was down 7.0% on a year-over-year basis. Research analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Sanofi

Large investors have recently modified their holdings of the stock. Patriot Financial Group Insurance Agency LLC grew its position in Sanofi by 5.7% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 31,678 shares of the company’s stock valued at $1,495,000 after acquiring an additional 1,700 shares during the last quarter. Old Port Advisors grew its position in Sanofi by 5.8% in the 3rd quarter. Old Port Advisors now owns 42,659 shares of the company’s stock valued at $2,014,000 after acquiring an additional 2,326 shares during the last quarter. Gradient Investments LLC grew its position in Sanofi by 81.1% in the 3rd quarter. Gradient Investments LLC now owns 22,380 shares of the company’s stock valued at $1,056,000 after acquiring an additional 10,025 shares during the last quarter. HF Advisory Group LLC grew its position in shares of Sanofi by 14.9% during the 3rd quarter. HF Advisory Group LLC now owns 30,970 shares of the company’s stock worth $1,462,000 after buying an additional 4,021 shares in the last quarter. Finally, Cullen Capital Management LLC grew its position in shares of Sanofi by 9.2% during the 2nd quarter. Cullen Capital Management LLC now owns 437,824 shares of the company’s stock worth $21,151,000 after buying an additional 36,714 shares in the last quarter. Institutional investors own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.